Atelier Therapeutics discovers next-generation GPCR therapeutics at the intersection of neuroinflammation and metabolic health. Leveraging state-of-the-art CryoEM and ML-enabled structure-based drug design, our lead program targets the microglial checkpoint to restore homeostasis in neurodegenerative and inflammatory diseases.